INTRODUCTION
The pituitary content of fsh is influenced both by the rate of synthesis and by the rate of secretion of the hormone. Consequently, measurement of the pituitary store of fsh cannot, alone, give conclusive evidence of changes in either process. In certain circumstances, however, such measurements may provide evidence which is at least suggestive. It has, for example, been shown that the rapid depletion of pituitary fsh in female rats shortly before they attain sexual maturity (Fawke & Brown, 1970) can be inhibited by treatment with sodium barbitone or reserpine (Brown, 1971) . It was thought that the most probable interpretation of this finding was that these drugs inhibit the secretion of fsh. Treatment with /»-chlorophenylalanine (CPA) which inhibits the synthesis of 5-hydroxytryptamine (5-HT) (Koe & Weissman, 1966) , or with methysergide which antagonizes 5-HT, also prevented the rapid fall in fsh content, suggesting that 5-HT may play an excitatory rôle in fsh secretion (Brown, 1971) . To investigate further the involvement of the biogenic monoamines in pituitary gonadotrophic function, the effect on pituitary fsh content of drugs which modify their actions has now been tested in mature male rats. For reasons explained below, the animals used were intact and castrated males, and castrated males treated with testosterone. The drugs tested were reserpine, which depletes tissues of both 5-HT and catecholamines ; CPA for its effect on the synthesis of 5-HT; -methyltyrosine which inhibits catecholamine synthesis (Spector, Sjoerdsma & Udenfriend, 1965) ; thymoxamine-an a-adrenergic blocker (Birmingham & Szolcsanyi, 1965) , and methallibure because this drug probably inhibits the synthesis of fsh (Brown, 1963; Walpole, 1968) .
Castration in the rat causes, after 7 or 8 days, an increase in the plasma fsh level with little change or a fall in pituitary fsh content (Steinberger & Duckett, 1968; Watanabe & McCann, 1969 (Steinberger & Duckett, 1968) . Similar changes were produced when treatment with testosterone was started 35 days after castration (Kamberi & McCann, 1969 Pohley (1953) . Details of the methods of storage and assay have been described previously (Fawke & Brown, 1970 Burack, Weiner & Hagen (I960) and diluted with saline. All drugs were injected subcutaneously in a volume of 0-2 to 0-5 ml, between 10.00 and 12.00 hours, at a site remote from that used for the injection of Sustanon.
The effects ofthe drugs were tested in three situations : (1) rats were castrated and injected with 10 mg Sustanon while still anaesthetized; drugs were injected daily for 5 days starting on the day after operation, (2) rats were castrated but not treated with testosterone; drugs were injected as in the previous group, (3) intact rats were injected with drugs daily for 5 days. In all groups, the rats were killed 24 hr after the final injection of the drug: in castrated animals, this was 6 days after operation. The pituitary fsh content and concentration in drug-treated rats was compared by direct assay with that in rats treated with the vehicle alone.
RESULTS
In preliminary experiments, rats were injected with TP starting on the day of castration. They were given either 0-5 mg TP daily or 1 ·5 mg on alternate days. The pituitary fsh content 7 days after castration was significantly raised in rats treated with TP (Table 1 (Table 3 ). The drug pro¬ duced no significant changes in the fsh levels in the intact rat (Table 4) .
a.-Methyltyrosine methyl ester hydrochloride
In doses up to 36 mg/day, MPT.ME produced no significant changes in pituitary fsh content or concentration except in the castrated testosteronetreated rat when both were significantly reduced by the higher dose (Table 2 ).
Thymoxamine
Thymoxamine, 800 /ig/day, produced significant increases in pituitary fsh, both in castrated, testosterone-treated rats (Table 2 ) and in intact rats (Table  4 ). In castrated rats without steroid treatment, however, this drug produced no significant change in fsh levels and, if anything, depressed them.
Organ weights in intact rats
Methallibure (6 mg/day) did not cause a significant fall in body weight (which was 94 % ofthat of the controls), but seminal vesicle weight was reduced to 61 % (P< 0 -001 ) and ventral prostate weight to 80% (P< 0 · 1 ) ofthat ofthe controls. Reserpine, 10 and 20 /ig/day, did not alter body weight but increased seminal vesicle weight to 124% ( <0·05) and 151% ( <0·01), respectively, of the control values: ventral prostate weight was raised to 113 and 127% but the increase was not statistically significant. In doses of 20 mg/day, CPA.ME caused a significant (P< 0-05) reduction in ventral prostate weight to 85 % ofthat of the control. Similar doses of CPA caused a significant fall in body weight (to 91 %; <0·05) but no significant change in organ weights. The compound MPT.ME was tested at a dose of 36 mg/day and thymoxamine at 800 µg/day but neither altered body, seminal vesicle or ventral prostate weights. None of the drugs in the doses used caused significant alteration of testis weight.
DISCUSSION
The reduction in pituitary fsh content caused by methallibure in castrated, testosterone-treated rats is compatible with the hypothesis that this drug re¬ duces the synthesis of fsh (Brown, 1963; Walpole, 1968) . A similar effect in intact rats confirms previous observations (Brown, 1963) and supports the same hypothesis. The increase in pituitary fsh content (as compared with vehicletreated controls) in the castrated rats not treated with testosterone suggests that methallibure also prevents the secretion of fsh, and that the increased secretion in this situation may be more sensitive to inhibition by the drug than the synthetic process. Methallibure prevents the fall in pituitary fsh in maturing female rats (Brown, 1971) and during the oestrous cycle in the pig (Garbers & First, 1969 (Brown, 1963; Fawke, Morris & Brown, 1972) .
The increase in pituitary fsh caused by reserpine in all three situations is probably best explained by inhibition of fsh secretion, stimulation of synthesis being less likely. Increases over control levels in pituitary fsh caused by reser¬ pine in female rats have been reported by Labhsetwar (1967) , and reserpine has been shown to prevent the fall in fsh in 35-day-old female rats (Brown, 1971) . Reserpine has also been reported to reduce the FSH-releasing activity in the blood of hypophysectomized rats (Negro-Vilar, Dickerman & Meites, 1968 The effects of CPA can also be explained on the assumption that it inhibits fsh secretion. This is supported by the fact that the effect was greatest, though not consistent, in castrated rats in which secretion is thought to be increased. This interpretation would agree with the findings in maturing female rats in which CPA prevented the rapid fall in pituitary fsh (Brown, 1971 (Kordon, Javoy, Vassent & Glowinski, 1968) . This possible involvement of 5-HT in the secretion of fsh is discussed more fully elsewhere (Brown, 1971) .
The results of treatment with MPT.ME are not very striking except for the significant fall in pituitary fsh content which occurred with the higher dose in the castrated, testosterone-treated animals. This dose did not cause any obvious toxic effects and only reduced the body weight of treated rats to 95 % of that of the controls : the effect may therefore be a specific result of the blockade of catecholamine synthesis. There was, however, no similarity between the effects of MPT.ME and those of the a-adrenergic-blocking drug, thymoxamine. This substance produced changes in fsh content which are difficult to interpret. It seems unlikely that, in this instance, the increase in pituitary content found in the castrated, testosterone-treated rat was due to inhibition of fsh secretion, considering that a similar effect was not found in the castrated rat in the absence of treatment with TP. The rise in the former animals and that found in intact rats may, therefore, have been due to stimulation of the synthesis of fsh by thymoxamine. This possibility was suggested when interpreting the effect of the same drug on pituitary fsh in immature female rats (Brown, 1971) and in this context it was suggested that thymoxamine might also increase fsh secre¬ tion. However, before ascribing these actions to adrenergic blockade, it must be noted that thymoxamine has other activities : it is, for example, antihistaminic (Birmingham & Szolcsanyi, 1965) .
There were no significant changes in testicular weight in the intact rats treated with drugs, so that these results do not help in the interpretation of changes in pituitary fsh levels. The reduction in seminal vesicle weight by methallibure was expected, but the increase in seminal vesicle weight in rats treated with reserpine was not foreseen as it had been expected to fall because of an inhibition of secretion of lh. A similar effect was found in mice (Fawke et al., 1972) but no indication was obtained as to the site of action of reserpine: this could be anywhere from the central nervous system to the seminal vesicle itself. The significant reduction in ventral prostate weight produced by CPA. ME is also paralleled by the reduction in seminal vesicle weight in hemicastrated mice (Fawke et al., 1972) . These findings suggest that depletion of tissue 5-HT may inhibit the secretion of lh under some circumstances, a sug¬ gestion which would explain the reported blockade of induced ovulation in immature mice by CPA (Brown, 1968) .
